Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes from GRIFFIN

Documenti analoghi

• Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study
  di: Ajay K. Nooka, et al.
  Pubblicazione: (2024)
• Successful treatment of scleromyxedema with daratumumab, lenalidomide and dexamethasone in a patient with multiple myeloma
  di: Luca Bettolini, et al.
  Pubblicazione: (2024)
• Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis
  di: Jahanzaib Khwaja, et al.
  Pubblicazione: (2025)
• Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma
  di: Danai Dima, et al.
  Pubblicazione: (2024)
• Modeling serum M‐protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasone
  di: Yuki Otani, et al.
  Pubblicazione: (2024)